OHE is pleased to announce that Dr Francois Maignen has joined the team as Head of Operational Research and Data Analysis. Francois’s principal areas of expertise are in the clinical development (methodology of clinical trials) and regulation of medicines for human use.
OHE is seeking to recruit a well-qualified, highly motivated and energetic economist, with particular strengths in the economics of industrial organisation and regulation. The economist will contribute to research and consultancy activities.
The challenge of globalisation heads Towse's list of four core targets for ISPOR.
OHE’s Director, Adrian Towse, is President of the International Society for Pharmacoeconomics and Outcomes Research (ISPOR) for the 2014–15 term, beginning 1 July. His 3rd June incoming president's address to the plenary session at the 19th Annual International Meeting is reproduced below.
Real Option Value and Path Dependence in Oncology Innovation. Based on an OHE Lunchtime Seminar, this Seminar Briefing addresses a persistent issue: how to adequately reward innovation through the pricing of new medicines given the limitations of the information available at launch.
Composed of academics and thought leaders from within and outside the UK, OHE’s Editorial Board has provided advice and guidance to the OHE's peer-reviewed publications programme since the 1960s. In January 2014, Anita Charlesworth, Chief Economist at the Nuffield Trust, and Professor Nicholas Mays, London School of Hygiene and Tropical Medicine, joined the Board.
OHE's extensive expertise in health outcomes will be further enhanced with the addition of Mike.
OHE is delighted to announce the appointment of Mike Herdman as Head of Health Outcomes, a new position at OHE. Mike brings with him extensive experience in psychometrics and in the development and validation of quality of life instruments.